Asandeutertinib

Primary objective: To evaluate the intracranial efficacy of TY-9591 compared with osimertinib as first-line treatment for patients with brain metastases with EGFR sensitive mutations. Secondary objectives: To evaluate other intracranial efficacy indicators and systemic efficacy of TY-9591 compared with osimertinib as first-line treatment for patients with brain metastases with EGFR sensitive mutations, as well as the improvement of neurological function in patients with brain metastases and the impact on patients' health-related quality of life; to evaluate the safety and tolerability of TY-9591 in the treatment of patients with brain metastases of EGFR mutation-positive NSCLC; to evaluate the pharmacokinetic (PK) characteristics of TY-9591 and its metabolites